Messenger RNA expression of vascular endothelial growth factor and its receptors in primary colorectal cancer and corresponding liver metastasis

Annals of Surgical Oncology

Volumn 15, Issue 4, 2008, Pages 1232-1238

  Kobayashi, Hirotoshi ^a,b   Sugihara, Kenichi ^a   Uetake, Hiroyuki ^a   Higuchi, Tetsuro ^a   Yasuno, Masamichi ^a   Enomoto, Masayuki ^a   Kuramochi, Hidekazu ^b   Lenz, Heinz Josef ^b   Danenberg, Kathleen D ^c   Danenberg, Peter V ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Response Genetics Inc   (United States)

Author keywords

Colorectal cancer; Liver metastasis; RT PCR; VEGF; VEGF receptor

Indexed keywords

FLUORESCENT DYE; FORMALDEHYDE; MESSENGER RNA; PARAFFIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; CLINICAL ARTICLE; COLORECTAL CANCER; CONFERENCE PAPER; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HUMAN; LASER CAPTURE MICRODISSECTION; LIVER METASTASIS; MALE; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; STATISTICAL SIGNIFICANCE; TUMOR;

COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICRODISSECTION; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 40549128307     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-9811-7     Document Type: Conference Paper

References (29)

1. Jemal A, Siegel R, Ward E. et al Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30
2. Weiss L, Grundmann E, Torhorst J. et al Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986;150:195-203
3. Gutman M, Fidler IJ. Biology of human colon cancer metastasis. World J Surg 1995;19:226-34
4. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. Cancer Res 1986;46:467-73
5. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5
6. Kang SM, Maeda K, Onoda N et al. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer 1997;74:502-7
7. Kaio E, Tanaka S, Kitadai Y. et al. Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 2003;64:61-73
8. Hurwitz H, Fehrenbacher L, Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
9. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76
10. Shibuya M, Yamaguchi S, Yamane A. et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990;5:519-24
11. Terman BI, Dougher-Vermazen M, Carrion ME. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992;187:1579-86
12. de Vries C, Escobedo JA, Ueno H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989-91
13. Park JE, Chen HH, Winer J, et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994;269:25646-54
14. Olofsson B, Korpelainen E, Pepper MS. et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A 1998;95:11709-14
15. Joukov V, Pajusola K, Kaipainen A. et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. Embo J 1996;15:290-8
16. Achen MG, Jeltsch M, Kukk E. et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A 1998;95:548-53
17. Shibuya M. Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E. Cancer Sci 2003;94:751-6
18. Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40
19. Lord RV, Salonga D, Danenberg KD. et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000;4:135-42
20. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996;6:995-1001
21. Kuramochi H, Hayashi K, Uchida K. et al. Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res 2006;12:29-33
22. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
23. Andre T, Bensmaine MA, Louvet C. et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17:3560-8
24. de Gramont A, Figer A, Seymour M. et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47
25. Douillard JY, Cunningham D, Roth AD. et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7
26. Goldberg RM, Sargent DJ, Morton RF. et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30
27. Saltz LB, Cox JV, Blanke C. et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14
28. Koehne C, Bajetta E, Lin E. Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients with previously treated metastatic colorectal cancer receiving FOLFOX4 and PTK787/ZK 222584 or placebo (CONFIRM 2) [abstract No. 3508]. Proc Am Soc Clin Oncol 2006
29. Lee JC, Chow NH, Wang ST, et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748-753